StemCell Therapy

BIO-TECHNE Corp (TECH) is around the top of the Biotechnology industry according to InvestorsObserver. TECH received an overall rating of 59, which means that it scores higher than 59 percent of all stocks. BIO-TECHNE Corp also achieved a score of 69 in the Biotechnology industry, putting it above 69 percent of Biotechnology stocks. Biotechnology is ranked 24 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

BIO-TECHNE Corp (TECH) stock is lower by -2.31% while the S&P 500 is higher by 0.47% as of 2:18 PM on Wednesday, Feb 3. TECH is lower by -$8.71 from the previous closing price of $376.76 on volume of 132,763 shares. Over the past year the S&P 500 is higher by 16.58% while TECH is higher by 76.63%. TECH earned $6.28 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 58.64.

Click Here to get the full Stock Score Report on BIO-TECHNE Corp (TECH) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is BIO-TECHNE Corp (TECH) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Johnson County Community College is a great place for students to begin their educational journey and discover unique career paths. For example, introductory science courses at JCCC open the door to opportunities in specialized fields likebiotechnology.

Introducing a High-Demand Career Path

The field of biotechnology brings us so many amazing innovations in medicine, agriculture and animal health, says Heather Seitz, Professor of Biotechnology at JCCC. Its amazing learning about all the products that have been developed like recombinant insulin for diabetics, human growth hormone used to treat lots of growth disorders, crops that are drought-resistant and new vaccine technologies.

JCCCsIntroduction to Biotechnologydives into career exploration, history and applications of technology, molecular biology and bioethics. This course allows students to develop biotechnology skills while researching and developing an actual biotech product.

Students will learn how to create a product and then they will be able to develop, test and package the product for use by other courses on campus, says Seitz. Its an exciting opportunity for an aspiring biotechnologist.

A Culture of Success

As the field of biotechnology continues to grow, Seitz wants to spread the word to students considering a career in medicine.

I see tons of students who want to cure diseases and we need people working in the labs and helping to test and develop new strategies, she says. This work is really what cures diseases but its not something people often say when asked what they want to be when they grow up. I would argue that they just dont know the name of this important career.

Students can enter the biotechnology industry after earning an associate degree. Common careers include manufacturing technician, cell culture technician, instrument calibration technician, clinical research associate, clinical research administrator and medical laboratory assistant.

Location is Key

Kansas City is home to the Animal Health Corridor, the largest collection of animal health biotechnology companies in the world. In total, there are over 300 biotech companies in the Kansas City metro area, making JCCC an ideal location for this field of study.

Students seeking a bachelors degree in biotechnology wont have to look far. JCCCs courses transfer seamlessly to theUniversity of Kansas Edwards Campus biotechnology program. A bachelors degree allows students to work for companies that manufacture vaccines, develop new diagnostic tests and create personalized medicines and other products.

Randy Logan, Director of KUs biotechnology program, tells students that each class they take before their transfer is an important one.

The classes you take in your freshman and sophomore year lay the foundation for your downstream coursework, he said. You will build on that foundation and expand in complex and exciting ways. Focus on mastering the content you are given and never treat the classes as a check-the-box exercise.

Treating Mans Best Friend

JCCC alum Fareeha Lodhi started her work in the field of cancer treatment after completing the biotechnology program at KU Edwards. Lodhi is a laboratory manufacturing associate at ELIAS Animal Health in Kansas City. She studies immunotherapy treatment that creates cancer vaccines for canine patients.

Biotechnology is a vast field and is playing a vital role in the healthcare industry, especially the pharmaceutical and agricultural industry, she said. I was always fascinated by the lab environment, cell cultures and medicinal industry. To work in this field every day is a dream.

Start Your Journey

Ready to explore the field of biotechnology?Learn moreand check out oursteps to enroll!

Go here to see the original:
Updates from Johnson County Community College: Developing the future with biotechnology - Shawnee Mission Post

Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants

Study identifies the N-terminal domain of the SARS-CoV-2 spike protein as a target of potent neutralizing antibodies, but a target that can vary

Separate research results published in Cell characterize the virulence and antibody response to N439K, a prevalent variant of the SARS-CoV-2 receptor binding motif

SAN FRANCISCO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research characterizing a novel site of vulnerability on the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) spike protein specifically the N-terminal domain (NTD). The study findings were made available online on bioRxiv on January 14, 2021 and have been submitted to a peer-reviewed journal for future print publication. This manuscript, together with data on immune evasion by mutations elsewhere in the spike protein published by scientists in Cell, begin to paint a comprehensive picture of the mechanisms that SARS-CoV-2 may utilize to evade immunity. Collectively, these data indicate the importance of carefully targeting conserved regions of the spike for vaccines and clinical monoclonal antibodies.

The receptor binding motif (RBM) of SARS-CoV-2, the region of the receptor binding domain (RBD) that interacts with the SARS-CoV-2 receptor, is a common target of COVID-19 natural and vaccine-induced immune responses, as well as monoclonal antibodies. However, recently published research has characterized the frequent occurrence of mutations within the RBM, highlighting the need for targeting alternate sites within the spike protein.

This new research indicates the NTD is another site on the SARS-CoV-2 spike protein that, like the RBM, contains mutations as well as deletions in emerging variants, said Davide Corti, Ph.D., senior vice president of antibody research for Vir. Mutations in these immunodominant domains can evade natural immune responses and are of concern for vaccines and for therapeutic monoclonal antibodies targeting these regions. This underscores the need to advance therapies that have a high barrier to resistance.

Story continues

Little is known about neutralizing antibodies that bind to the NTD and their contribution to protection from infection and disease. In this new study, researchers at Vir, the University of Washington and other universities in the United States and Europe isolated and extensively characterized 41 human monoclonal antibodies that recognize the SARS-CoV-2 NTD. A subset of these NTD-specific monoclonal antibodies neutralize SARS-CoV-2 with potency similar to potential best-in-class monoclonal antibodies that target the RBD. Notably, several new SARS-CoV-2 genetic variants, including the widely prevalent variants identified in South Africa and the UK, were found to possess frequent mutations in the NTD.

These new findings build upon recent research published in Cell by Vir scientists in collaboration with colleagues at MRC-University of Glasgow Centre for Virus Research, which demonstrate the RBM of the SARS-CoV-2 spike protein a major target of neutralizing monoclonal antibodies is particularly variable.

Our ongoing effort to characterize the SARS-CoV-2 spike protein is proving ever more critical as new variants continue to emerge. These new findings reinforce the approach we have taken with our monoclonal antibody, VIR-7831, which is currently in Phase 3 trials, said George Scangos, Ph.D., chief executive officer of Vir. By targeting a very conserved region of the RBD, VIR-7831 was designed to be effective against SARS-CoV-2 and variants that might emerge in this outbreak or future outbreaks of related viruses.

The findings published in Cell characterize the virulence, fitness, clinical and epidemiologic impact, molecular features and immune response to N439K, a prevalent RBM variant of the SARS-CoV-2 spike protein first identified in Scotland in March 2020. Since then, a second lineage has independently emerged in other European countries, which, by January 2021, was detected in more than 30 countries across the globe. Although N439K variants are not believed to be more virulent or transmissible than the original SARS-CoV-2 strain, this research is the first to demonstrate mutations that maintain viral fitness can evade immunity.

To understand whether and how the N439K mutation might evade immunity, researchers in the findings published in Cell noted the binding of polyclonal sera to the SARS-CoV-2 spike was reduced by the mutation in a sizeable fraction of the 445 samples obtained from recovered individuals. Additionally, out of 144 human neutralizing mAbs isolated from individuals who recovered from SARS-CoV-2 infection early in the pandemic, a significant number failed to efficiently recognize N439K. When tested across four clinical-stage antibodies S309 (the precursor of VIR-7831), LY-CoV555, REGN10933 and REGN10987 S309, which targets a non-RBM epitope, LY-CoV555 and REGN10933 were capable of neutralizing the N439K variant.

About VIR-7831VIR-7831 is an investigational dual-action monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and an enhanced ability to clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV (the virus which causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

Vir Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, promising and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding statements regarding print publication of Virs research in a peer-reviewed journal, the emergence of new SARS-CoV-2 variants, the identification of N-terminal domain as a target of potent neutralizing antibodies, the importance of advancing therapies that have a high barrier to resistance and the potential ability of VIR-7831 to evade such variants in the protection and treatment of COVID-19 and in the prevention of future pandemics of related coronaviruses. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to our business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes.

See original here:
Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of...

The 42 rating InvestorsObserver gives to Allovir Inc (ALVR) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 41 percent of stocks in the Biotechnology industry, ALVRs 42 overall rating means the stock scores better than 42 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Allovir Inc (ALVR) stock is down -5% while the S&P 500 is up 0.36% as of 1:25 PM on Wednesday, Feb 3. ALVR has fallen -$2.23 from the previous closing price of $44.63 on volume of 119,688 shares. Over the past year the S&P 500 is up 17.84% while ALVR is up 1377.35%. ALVR lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allovir Inc (ALVR) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continue reading here:
Is Allovir Inc (ALVR) The Right Choice in Biotechnology? - InvestorsObserver

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a Biotechnology Grand Challenge Winner. One of four winning teams, the joint team comprised of MIT and Synlogic was awarded $1 million in an effort to spearhead innovation among small businesses in the field of biotechnology for the Department of Defense.

"We are honored to be recognized by the AFRL and are thrilled to collaborate with Synlogic to achieve this success," said Christopher Voigt, MIT Professor of Biological Engineering and Principal Investigator for the MIT Voigt Lab. "Our challenge was determining which organization would possess the proven expertise in both the development and manufacturing of novel biotherapeutic products, and we couldn't be happier that we have found that partner in Synlogic."

Christopher Voigt is an expert in synthetic biology and biotechnology with extensive research programs in defense, chemistry/materials, and agriculture. The focus of the Voigt Lab is to develop new experimental and theoretical methods to push the scale of genetic engineering, with the ultimate objective of genome design. This will impact the engineering of biology for a broad range of applications, including agriculture, materials, chemicals, and medicine. Professor Voigt's research spans applications for the Army, Navy, and Air Force, and he works closely with scientists across the service labs as well as hosting DoD researchers at MIT.

"Our internal and fully integrated Process Development & Manufacturing Sciences organization has demonstrated leading technical expertise in the field of Synthetic Biotic medicines and we look forward to applying innovative solutions for today's real-life challenges," said Antoine Awad, Synlogic's Chief Operating Officer."As we develop our internal pipeline we are excited to leverage our core capabilities to advance innovative partner projects, such as applying our bioprocess and manufacturing to advance the goals of the AFRL."

Together, Synlogic and the Voigt Lab will collaborate to generate and manufacture engineered strains by performing an assessment of process manufacturability, with optimization performed to maximize high cell density growth and high end of fermentation (EOF) viability. The goal of this work is to produce a live bacterial therapeutic that would improve pilot performance and decision-making when battling fatigue during long missions.

Learn more about Synlogic at http://www.synlogictx.com.

About Synlogic

Synlogic is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials including the Phase 1 study for SYNB1891 and SYNB8802 and the Phase 2 study of SYNB1618, and availability of clinical trial data from that study and other studies.

Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability ofSynlogicto protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" inSynlogic'sfilings with theSEC. The forward-looking statements contained in this press release reflectSynlogic'scurrent views with respect to future events.Synlogicanticipates that subsequent events and developments will cause its views to change. However, whileSynlogicmay elect to update these forward-looking statements in the future,Synlogicspecifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

SOURCE Synlogic, Inc.

Home

More:
Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory - PRNewswire

Arcutis Biotherapeutics Inc (ARQT) is near the top in its industry group according to InvestorsObserver. ARQT gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Arcutis Biotherapeutics Inc gets a 76 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Arcutis Biotherapeutics Inc (ARQT) stock is lower by -3.74% while the S&P 500 is up 0.18% as of 11:53 AM on Wednesday, Feb 3. ARQT is down -$1.35 from the previous closing price of $36.10 on volume of 940,229 shares. Over the past year the S&P 500 has risen 16.24% while ARQT is up 35.53%. ARQT lost -$3.45 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Arcutis Biotherapeutics Inc (ARQT) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is Arcutis Biotherapeutics Inc (ARQT) a Winner in the Biotechnology Industry? - InvestorsObserver

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PDS Biotechnology (PDSB) and HCA Healthcare (HCA) with bullish sentiments.

PDS Biotechnology (PDSB)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on PDS Biotechnology, with a price target of $6.00. The companys shares closed last Wednesday at $3.48.

According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 47.3% and a 69.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for PDS Biotechnology with a $6.53 average price target.

See todays analyst top recommended stocks >>

HCA Healthcare (HCA)

Credit Suisse analyst A.J. Rice maintained a Buy rating on HCA Healthcare today and set a price target of $201.00. The companys shares closed last Wednesday at $170.81, close to its 52-week high of $174.55.

According to TipRanks.com, Rice is a 4-star analyst with an average return of 9.9% and a 63.9% success rate. Rice covers the Healthcare sector, focusing on stocks such as Genesis Healthcare, Acadia Healthcare, and Encompass Health.

HCA Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $191.31, which is a 15.1% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $200.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read the original post:
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and HCA Healthcare (HCA) - Smarter Analyst

Overall market sentiment has been high on PDS Biotechnology Corp (PDSB) stock lately. PDSB receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObservers Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

PDS Biotechnology Corp (PDSB) stock is trading at $3.81 as of 3:18 PM on Tuesday, Feb 2, a rise of $0.19, or 5.25% from the previous closing price of $3.62. The stock has traded between $3.48 and $3.92 so far today. Volume today is more active than usual. So far 665,239 shares have traded compared to average volume of 485,122 shares.

To see InvestorsObserver's Sentiment Score for PDS Biotechnology Corp click here.

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Click Here to get the full Stock Score Report on PDS Biotechnology Corp (PDSB) Stock.

Read more here:
PDS Biotechnology Corp (PDSB) Stock: What Does the Chart Say? - InvestorsObserver

The 39 rating InvestorsObserver gives to Ovid Therapeutics Inc (OVID) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 36 percent of stocks in the Biotechnology industry, OVIDs 39 overall rating means the stock scores better than 39 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Ovid Therapeutics Inc (OVID) stock is trading at $2.89 as of 2:58 PM on Tuesday, Feb 2, an increase of $0.09, or 3.21% from the previous closing price of $2.80. The stock has traded between $2.70 and $3.10 so far today. Volume today is more active than usual. So far 3,194,206 shares have traded compared to average volume of 1,863,832 shares.

Click Here to get the full Stock Score Report on Ovid Therapeutics Inc (OVID) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continue reading here:
Should You Buy Ovid Therapeutics Inc (OVID) in Biotechnology Industry? - InvestorsObserver

A rating of 81 puts Codexis, Inc. (CDXS) near the top of the Biotechnology industry according to InvestorsObserver. Codexis, Inc.'s score of 81 means it scores higher than 81% of stocks in the industry. Codexis, Inc. also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 33 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Codexis, Inc. (CDXS) stock is trading at $26.13 as of 10:16 AM on Tuesday, Feb 2, a rise of $2.22, or 9.28% from the previous closing price of $23.91. The stock has traded between $24.93 and $26.71 so far today. Volume today is light. So far 253,983 shares have traded compared to average volume of 799,470 shares.

Click Here to get the full Stock Score Report on Codexis, Inc. (CDXS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more:
Is Codexis, Inc. (CDXS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 50 puts Prothena Corporation PLC (PRTA) near the middle of the Biotechnology industry according to InvestorsObserver. Prothena Corporation PLC's score of 50 means it scores higher than 50% of stocks in the industry. Prothena Corporation PLC also received an overall rating of 45, putting it above 45% of all stocks. Biotechnology is ranked 33 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Prothena Corporation PLC (PRTA) stock is trading at $13.85 as of 10:16 AM on Tuesday, Feb 2, a gain of $2.85, or 25.87% from the previous closing price of $11.00. The stock has traded between $13.00 and $14.70 so far today. Volume today is above average. So far 532,574 shares have traded compared to average volume of 250,348 shares.

Click Here to get the full Stock Score Report on Prothena Corporation PLC (PRTA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Visit link:
Is Prothena Corporation PLC (PRTA) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 64 rating InvestorsObserver gives to Amicus Therapeutics, Inc. (FOLD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, FOLDs 64 overall rating means the stock scores better than 64 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Amicus Therapeutics, Inc. (FOLD) stock is trading at $20.64 as of 11:38 AM on Tuesday, Feb 2, a gain of $1.39, or 7.22% from the previous closing price of $19.25. The stock has traded between $19.22 and $20.84 so far today. Volume today is 2,304,746 compared to average volume of 2,548,983.

Click Here to get the full Stock Score Report on Amicus Therapeutics, Inc. (FOLD) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Amicus Therapeutics, Inc. (FOLD) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations who have been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI). The data were presented in an oral discussion at the 2020 World Conference on Lung Cancer (WCLC 2020) presented by the International Association for the Study of Lung Cancer (IASLC) that is currently taking place in Singapore. The presentation, entitled, Neratinib in Pretreated EGFR Exon 18-Mutated Non-Small Cell Lung Cancer (NSCLC): Initial Findings from the SUMMIT Basket Trial, is being presented at an Oral Session by Valentina Boni, MD, PhD, START Madrid-CIOCC, Centro Oncologico Clara Campal, HM Sanchinarro.

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating EGFR exon 18 or HER2 mutations. In the EGFR exon 18 mutation cohort, patients with lung cancer with single or complex EGFR exon 18 mutations, who were EGFR TKI nave or were previously exposed to EGFR TKI, were enrolled into this study and received 240 mg of neratinib daily as a single agent.

In this cohort of 11, patients had received a median of 2 prior lines of therapy in the metastatic setting (range 1-3 prior regimens) before entering the trial. 10 patients had been previously treated with an EGFR targeted tyrosine kinase inhibitor (gefitinib, erlotinib, osimertinib and/or afatinib).

The interim efficacy results from the trial showed that for the 10 evaluable patients who had previously been treated with an EGFR tyrosine kinase inhibitor, 6 patients (60%) experienced a partial response, which included 4 patients (40%) with a confirmed partial response. 8 patients (80%) experienced clinical benefit (clinical benefit is defined as confirmed complete response or partial response or stable disease for at least 16 weeks). The median duration of response was 7.5 months and the median progression-free survival was 9.1 months. The success criteria for both the 1st stage and the 2nd stage of the Simons 2-stage design were met and enrollment in the 2nd stage of this cohort continues.

The safety profile observed in the subgroup of patients with EGFR exon 18-mutated NSCLC showed that for the 11 patients who received neratinib in the trial, there were no reports of grade 3 or higher diarrhea. 4 patients (36%) reported grade 1 and 1 patient (9%) reported grade 2 diarrhea. No patients required a dose hold, dose reduction, hospitalization or permanently discontinued neratinib due to diarrhea.

Dr. Boni, an investigator of the trial, said, We are very excited about these early study results in EGFR exon 18 mutant lung cancer, for whom very few effective treatment options are available once they fail first-line FDA approved EGFR TKI therapy.

Jonathan Goldman, MD, Associate Professor of Hematology & Oncology, Associate Director of Drug Development, and Director of Clinical Trials in Thoracic Oncology at UCLA, said, These early study results open up a potentially effective option for EGFR exon 18 mutation-positive NSCLC patients once they fail first-line FDA approved TKI therapy.

Alan H. Auerbach, CEO and President of Puma Biotechnology, added, We are pleased to present this data at the World Conference on Lung Cancer and increase the awareness of neratinibs activity in this patient population within the lung cancer community. We are continuing to enroll this cohort of patients in the SUMMIT trial and we continue to believe that there is a need for new treatments for patients with EGFR exon 18-mutated NSCLC who have previously been treated with EGFR targeted tyrosine kinase inhibitors.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

See the rest here:
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung...

The 38 rating InvestorsObserver gives to Aikido Pharma Inc (AIKI) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, AIKIs 38 overall rating means the stock scores better than 38 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aikido Pharma Inc (AIKI) stock is lower by -9.23% while the S&P 500 has gained 1.79% as of 3:19 PM on Monday, Feb 1. AIKI is down -$0.15 from the previous closing price of $1.68 on volume of 7,900,423 shares. Over the past year the S&P 500 has risen 16.37% while AIKI has gained 51.49%. AIKI lost -$0.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aikido Pharma Inc (AIKI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See more here:
Where Does Aikido Pharma Inc (AIKI) Stock Fall in the Biotechnology Field? - InvestorsObserver

The market has been high on Puma Biotechnology Inc (PBYI) stock recently. PBYI gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesnt incorporate anything to do with the health or profitability of the underlying company.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObservers Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

Puma Biotechnology Inc (PBYI) stock has gained 9.25% while the S&P 500 is down -0.49% as of 11:32 AM on Monday, Jan 25. PBYI has risen $1.03 from the previous closing price of $11.14 on volume of 295,323 shares. Over the past year the S&P 500 is up 17.85% while PBYI has risen 51.18%. PBYI lost -$1.43 per share in the over the last 12 months.

To screen for more stocks like Puma Biotechnology Inc click here.

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Click Here to get the full Stock Score Report on Puma Biotechnology Inc (PBYI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Here is the original post:
What is the Market's View on Puma Biotechnology Inc (PBYI) Stock's Price and Volume Trends - InvestorsObserver

The 59 rating InvestorsObserver gives to INmune Bio Inc (INMB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 72 percent of stocks in the Biotechnology industry, INMBs 59 overall rating means the stock scores better than 59 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

INmune Bio Inc (INMB) stock is up 0.53% while the S&P 500 is lower by -0.61% as of 11:25 AM on Monday, Jan 25. INMB is up $0.11 from the previous closing price of $20.72 on volume of 238,786 shares. Over the past year the S&P 500 is up 17.71% while INMB is up 332.16%. INMB lost -$0.97 per share the over the last 12 months.

Click Here to get the full Stock Score Report on INmune Bio Inc (INMB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is INmune Bio Inc (INMB) The Right Choice in Biotechnology? - InvestorsObserver

Achieve Life Sciences Inc (ACHV) is near the top in its industry group according to InvestorsObserver. ACHV gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Achieve Life Sciences Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 33 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Achieve Life Sciences Inc (ACHV) stock has risen 5.69% while the S&P 500 has fallen -0.61% as of 11:25 AM on Monday, Jan 25. ACHV is higher by $0.67 from the previous closing price of $11.78 on volume of 375,583 shares. Over the past year the S&P 500 has risen 17.71% while ACHV is higher by 10.18%. ACHV lost -$8.76 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Achieve Life Sciences Inc (ACHV) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original here:
Where Does Achieve Life Sciences Inc (ACHV) Stock Fall in the Biotechnology Field? - InvestorsObserver

After a period of extreme volatility during 2020, it unexpectedly turned out to be a positive year for the equity markets and an extraordinary year for scientific progress. During the year, the Trust's share price appreciated 36.1% (share price total return, GBP) versus the benchmark, Nasdaq Biotech Index, that appreciated 23.2% - an outperformance of 12.9%. Similarly, the net asset value of the Trust appreciated 29.8%, outperforming the benchmark by 6.6% (all total return).

We can all agree that 2021 will be very difficult to predict with a pandemic raging the world, initial vaccination campaigns having just started, and a virus mutating and changing its infectability (Source: http://www.nextstrain.org).

The prevailing consensus view predicts that vaccination campaigns, with several vaccines on a global scale, will eventually lead to a broad immunity that will change the pandemic-nature of the Covid-19 infection to become endemic and manageable in a manner similar to many other viral infections. The view, at least from equity markets' perspective, is that they would have a strong finish at the end of 2021, on the back of strong economic recovery.

However, negative scenarios can also be envisioned: In the near-term, China might see a rise in the number of infected people which would lead to another hard lockdown resulting in negative economic impact. Given Japan's recent historical negative experiences of vaccinations, the nation's government may not be able to convince its citizens to vaccinate, creating a lingering national epidemic. The Covid-19 virus might mutate to increase the severity of the infection rate or render the current vaccination programs less effective - a scary scenario but as an investor one needs to take these potential outlier events into consideration.

Our outlook is positive, but as always, we closely monitor any developments which may impact our view. It is difficult not to have a positive outlook for the sector in the near-, mid-, and long-term, as innovation is constantly delivering more and more therapies, evidenced by:

Figure 1: New drug approvals in the US 2010-2020

Figure 1

Data sourced from Food and Drug Administration (FDA)

The result of the U.S. election was a narrow, but still decisive, win for the Democrat Party. In addition, the Senate was a tie, but with Vice President Kamala Harris having the final vote, the Democrats gained control of the Senate. Healthcare is clearly on the agenda for the Democrats, with Obamacare in focus. We do not expect to see new legislation introducing major changes to the healthcare system, but we keep a close eye on legislation leading to price pressure in particular subsectors. We remain agnostic to therapeutic areas but see more opportunities in oncology and rare diseases, with short- to mid-term scientific advancements in neurology and psychiatry leading to increased therapies for these historically difficult to treat areas. Additionally, gene sequencing is generating new genetic targets to a variety of diseases at record speed.

Biotech valuations are said by some to be in a 'bubble'. Clearly the small cap names have become more expensive - an area we currently are cautious about. Larger companies, with proven sales and revenue track records, are less expensive compared to the small cap names and we see more investment opportunities in this subsector. Interest rates are low, with Central Banks declaring that they will be lower for longer and monetary policy is expected to remain lax. Fiscal policy remains a focal point with stimulus packages being announced in response to the pandemic. Money Supply in response to the pandemic has had a sharp expansion (see figure 2 below). In our view, inflation of financial and other fixed assets is inevitable in the short to medium term.

Figure 2: Federal Reserve Money Supply M2 - 5 years

Figure 2

Source: Bloomberg

Disclaimer

International Biotechnology Trust plc published this content on 22 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 January 2021 07:21:01 UTC

See the rest here:
International Biotechnology Trust : Themes for 2021 - marketscreener.com

If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? Businesses in decline often have two underlying trends, firstly, a declining return on capital employed (ROCE) and a declining base of capital employed. Ultimately this means that the company is earning less per dollar invested and on top of that, it's shrinking its base of capital employed. In light of that, from a first glance at Level Biotechnology (GTSM:3118), we've spotted some signs that it could be struggling, so let's investigate.

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Level Biotechnology, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) (Total Assets - Current Liabilities)

0.11 = NT$58m (NT$714m - NT$184m) (Based on the trailing twelve months to September 2020).

Thus, Level Biotechnology has an ROCE of 11%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 8.5% it's much better.

View our latest analysis for Level Biotechnology

Historical performance is a great place to start when researching a stock so above you can see the gauge for Level Biotechnology's ROCE against it's prior returns. If you'd like to look at how Level Biotechnology has performed in the past in other metrics, you can view this free graph of past earnings, revenue and cash flow.

We are a bit worried about the trend of returns on capital at Level Biotechnology. Unfortunately the returns on capital have diminished from the 18% that they were earning five years ago. On top of that, it's worth noting that the amount of capital employed within the business has remained relatively steady. Companies that exhibit these attributes tend to not be shrinking, but they can be mature and facing pressure on their margins from competition. So because these trends aren't typically conducive to creating a multi-bagger, we wouldn't hold our breath on Level Biotechnology becoming one if things continue as they have.

In the end, the trend of lower returns on the same amount of capital isn't typically an indication that we're looking at a growth stock. Investors must expect better things on the horizon though because the stock has risen 3.4% in the last five years. Either way, we aren't huge fans of the current trends and so with that we think you might find better investments elsewhere.

If you'd like to know more about Level Biotechnology, we've spotted 3 warning signs, and 1 of them is potentially serious.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

PromotedIf youre looking to trade Level Biotechnology, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Read more:
Does Level Biotechnology's (GTSM:3118) Returns On Capital Reflect Well On The Business? - Simply Wall St

Dublin, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development, and drug delivery, and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report includes an analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Market figures are based on revenues at the manufacturer level and are projected in 2019 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market included in this report are forecasted by product, product category, and company.

The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information are reviewed for various candidate nano-drugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies. All market share data presented is on a global basis unless specifically noted.

Story continues

The Report Includes:

43 tables

An overview of the global nanoparticles in biotechnology, drug development, and drug delivery market

Estimation of the market size and analyses of market trends, with data from 2019, estimates for 2020, and projection of CAGR through 2025

Highlights of the drug development, formulation, and the development of new drug delivery systems and detailed product analyses within health and wellness subsegments

Information on nanomedicine and biomedical nanoparticle products and coverage of the next-generation vaccines

Evaluation of current market trends, market size, market forecast, and detailed analysis of drivers, challenges, and opportunities affecting the market growth

Discussion on the role of nanotechnology in COVID-19 vaccine production, components, and methods in the vaccine design for COVID-19 and challenges for vaccine disruptions

Assessment of various approaches for the treatment of COVID-19, and detailed description of structure and penetration of coronavirus

Details of clinical trials of nanoparticle drugs and drug delivery systems

A look at the patents, licensing, mergers and acquisitions, and market share analysis of the key companies of the industry

Company profiles of major players including Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Hofmann-La Roche Inc., Merck & Co., and Novartis AG

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Introduction to Nanoparticles

Liposomes

Quantum Dots

Dendrimers

Macromolecule Nanoparticles

Brief History of Nanoparticles

Nanoparticles in Biotechnology

Nanoparticles in Drug Development

Nanoparticles in Drug Delivery Systems

Nanoparticles in Diagnostic Imaging

Major Players in Nanoparticle Drug Delivery Field

Major Nanoparticle/Nanocrystal Drug Revenues

Chapter 4 Market Breakdown by Product Type

Nanoparticles in Biotechnology

Nanoparticles in Drug Development

Nanoparticles in Drug Delivery Systems

Nanoparticles in Diagnostic Imaging

Distribution of Nanobiotechnology and Nanomedicine Companies

Chapter 5 Structure of Nanoparticles

Chapter 6 Production of Nanoparticles

Methods of Nanoparticle Formation

Self-Assembly Production

Methods of Stabilization

Methods of Drug Introduction

Polymeric Nanoparticles

Micelles

Liposomes

Gold and Silicon Nanoparticles

Dendrimers

Methods for Loading Biological Molecules into Nanoparticles

Nanocrystal Drugs

Problems with Large-Scale Nanoparticles Production

Chapter 7 Nanoparticles in Biotechnology

Research and Development

Stem Cell Research

Cellular Repair

Paramagnetic and Superparamagnetic Nanoparticles

Biosensors and Quantum Dots

Nanoparticle Research Collaborative Programs

Chapter 8 Nanoparticles in Drug Development and Formulation

Bio Separations

Rapid Drug Analysis

Removal of Impurities and Toxins

Using Nanoparticles to Incorporate Insoluble Drugs

Gold and Silver Nanoparticles in Biomedicine

DNA Nanoparticle Development of DNA-Specific Drugs

Chapter 9 Nanoparticles in Drug Delivery Systems

Nanoparticles in Drug Delivery Applications

Designing a Nanoparticle Drug Delivery System

Nanoparticle Drug Stability

Size Homogeneity of Nanoparticle Preparations

Drug Loading of Nanoparticles

Drug Release from Nanoparticles

External Triggers for Releasing Drugs from Nanoparticles

Binding/Incorporation of Biomolecules to Nanoparticles

Nanoparticle Toxicity

Large Scale Manufacturing

Methods of Administration of Nanoparticle Drugs

Oral Administration

Injection Administration

Transdermal Patch

Implantation Administration

Inhalation Administration

Nanoparticles Suitable for Drug Delivery Systems

Lipid-Based Nanoparticles

Micelle Nanoparticles

Dendrimer Nanoparticles

Polymeric Nanoparticles

Metal-Based Nanoparticles

Biological Macromolecule Nanoparticles

Nanocrystals

Nanoparticle Drug Delivery Systems Now Available

Antibiotic Nanoparticles

Anti-Tumor and Small Molecule Delivery by Nanoparticle

Release of Anti-Cancer Drugs from Nanoparticles

Biomacromolecules Delivered by Nanoparticles

More:
Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems, 2020 Report - Overview, Structure, Production, COVID-19, Patents,...